Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma

dc.authorscopusid11839425100
dc.authorscopusid57219463817
dc.authorscopusid57204436831
dc.authorscopusid58010281600
dc.contributor.authorKöseoğlu,H.
dc.contributor.authorCenkeri,H.Ç.
dc.contributor.authorEroğlu,T.
dc.contributor.authorYalçın,B.
dc.date.accessioned2024-05-25T12:18:19Z
dc.date.available2024-05-25T12:18:19Z
dc.date.issued2023
dc.departmentOkan Universityen_US
dc.department-tempKöseoğlu H., Health Sciences University, Hamidiye Faculty of Medicine, Istanbul Health Practice and Research Center, Department of Urology, Istanbul, Turkey; Cenkeri H.Ç., Okan University, Faculty of Medicine, Department of Radiology, Turkey; Eroğlu T., Semdinli State Hospital, Department of Urology, Hakkari, Turkey; Yalçın B., Health Sciences University, Hamidiye Faculty of Medicine, Istanbul Health Practice and Research Center, Department of Radiation Oncology, Istanbul, Turkeyen_US
dc.description.abstractPurpose: Implementation of multiparametric magnetic resonance imaging (mpMRI) for prostate adenocarcinoma’s variant pathology requires awareness. The aim of this retrospective study was to investigate the discriminant efficacy of multiparametric magnetic resonance imaging modality for variant pathology associated with prostate adenocarcinoma. Methods: Consecutive 247 prostate cancer patients who underwent radical prostatectomy in our university-based hospital between October 2014 and October 2019, were retrospectively reviewed. Data of mpMRI-associated contrast enhancements, T2 signals, apparent diffusion coefficients (ADC), ages, and PSA values were compared. Clinical and demographic data of patients were noted including associated variant pathologies and reports of preoperative mpMRI images. Results: Among the patients, 63 (26%) had variant pathology and 14 (22%) had mpMRI before primary prostate biopsy. The group with variant pathology and the control group had similar perfusion curves and increased contrast when compared for mpMRI parameters, but different ADC values for each of the adjusted b-values for 400, 800 and 1400. Conclusion: Our study demonstrates that mpMRI appears to have no role in distinguishing rare variant pathologies associated with prostate adenocarcinoma despite different ADC values. © 2023, Urology Journal. All Rights Reserved.en_US
dc.identifier.citationcount0
dc.identifier.doi10.22037/uj.v20i.7468
dc.identifier.endpage161en_US
dc.identifier.issn1735-1308
dc.identifier.issue3en_US
dc.identifier.pmidPubMed:36840448
dc.identifier.scopus2-s2.0-85160458849
dc.identifier.scopusqualityQ3
dc.identifier.startpage157en_US
dc.identifier.urihttps://doi.org/10.22037/uj.v20i.7468
dc.identifier.urihttps://hdl.handle.net/20.500.14517/1691
dc.identifier.volume20en_US
dc.identifier.wosqualityQ4
dc.language.isoen
dc.publisherUrology and Nephrology Research Centreen_US
dc.relation.ispartofUrology Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.scopus.citedbyCount0
dc.subjectapparent diffusion coefficienten_US
dc.subjectmpMRIen_US
dc.subjectprostate adenocarcinomaen_US
dc.subjectprostate cancer variantsen_US
dc.titleDiscriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinomaen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files